FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.

T. Rowe Price

venBio Partners

Blue Pool Capital

6 Dimensions Capital

Casdin Capital

Google Ventures

HBM Healthcare Investments AG

Invus

Deerfield

Farallon Capital Management

The Pags Group

ARCH Venture Partners

Cormorant Asset Management

Deerfield Management

Fidelity

Fidelity Management and Research Company

FogPharma

We gathered for our first annual winter party at the Boston Flight Club, a social darts venue. It was a great time of playing, mingling, and a little friendly competition. We take pride in our close-knit company culture and are excited to see our team members growing closer together as we pave a new way for transformative medicines as part of our collective moonshot mission. 

We're pleased to welcome Richa Poddar, MBS, to our team as Vice President, New Product Planning. Richa will play an integral role in achieving our ambitious goal to be a unique creator of life-changing medicines, by optimizing the competitive positioning of our portfolio of programs as they are developed for the market. Earlier in her career, she played an instrumental role in launching #oncology and rare disease products, and we look forward to having her on our team to help create transformative precision therapeutics for patients suffering from devastating and often fatal diseases such as #cancer.

February 4 is #WorldCancerDay, and we at FogPharma are taking a stand to #closethecaregap in cancer treatment. 

At a systemic level, we know that inequalities in healthcare access disproportionately affect many people. We are committed to providing equitable access to our clinical trials and potentially transformative precision medicines for often fatal and devastating diseases such as cancer. Our mission is to make these treatments available to everyone who needs them. We have designed our ongoing Phase 1/2 clinical trial of FOG-001 with #healthequity in mind by selecting a diverse group of clinical trial investigators at some of the nation’s most renowned cancer centers and enabling them to provide patients and their caregivers with translation services and travel reimbursement.

Read more about World Cancer Day, and join us in learning how you can help reduce inequities in #cancer care here: https://lnkd.in/drnuZeE

Image by World Cancer Day 

Join us in welcoming Mark Ator, Ph.D., to the Fog team as our Associate Vice President, Discovery DMPK! Mark brings over 35 years of #drugdiscovery and early drug development experience, with specialties in biochemistry, drug metabolism, and pharmacokinetics. He also has extensive experience as a discovery project team leader, advancing four projects into preclinical development. We're happy to have him on board as we continue to integrate the latest breakthroughs in experimental science and #datascience to create a new class of transformative medicines for patients. 

Compass Therapeutics is a pharmaceutical company focused on developing antibody therapeutics for cancer and other diseases.

Compass Therapeutics

Artiva is a biotechnology company specializing in developing novel therapies for cancer treatment.

Artiva

TScan is a biotechnology company dedicated to developing T cell receptor therapies for cancer and other diseases.

TScan

Polaris Pharmaceuticals Inc is a company engaged in the development of innovative cancer therapeutics.

Polaris Pharmaceuticals Inc

Lycera Corp is a biopharmaceutical company focused on developing novel immunomodulatory therapies for treating cancer and autoimmune diseases.

Lycera Corp

FogPharma is a clinical-stage company pioneering a new class of drugs, Helicons, to address the limitations of today’s precision medicines and achieve universal druggability. Their mission is to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that block abnormal physiological processes in ways previously imagined but considered impossible.

Chief Medical Officer

Member Board Of Directors

Senior Vice President, Clinical Development

Clinical Development Lead, Immuno-Oncology and Combinations DPU

Director, Clinical Development, Oncology

Associate Director - Clinical Pharmacology and Experimental Medicine/Oncology

Assistant in Biology

Research Fellow

Medical Intern

Chief Medical Officer at FogPharma

Keith Orford

Associate Director, Machine Learning

Associate Director, Machine Learning and Computational Biology

Principal Scientist, Machine Learning

Senior Machine Learning Engineer

Senior Principal Scientific Computing Engineer

Principal Scientific Computing Engineer

Senior Programming Specialist

Visiting Researcher

Cooperative Education Student

Research Assistant

IAS Summer Research Fellow - Research Assistant

Intern

Computational Biology | Machine Learning | Data Science

Varun Shivashankar

Associate Director, De Novo Discovery

Senior Scientist,  Display Screening Team Lead

Protein Engineering, Evolution, and Assay Develpment Scientist; Site ESH Coordinator

Protein Optimization and Evolution Scientist

Postdoctoral Fellow

NIH F32 Postdoctoral Fellow

Associate Director, De Novo Discovery at FogPharma

Olena Tokareva

Senior Administrative Business Partner

Administrative Business Partner

Executive Assistant

Special Assistant to the Founder, Chairwomen & CEO of Care.com

Front Office Manager

Executive Housekeeper

Assistant Director of Housekeeping

Housekeeping Manager

Front Desk

PBX/Front Desk

VIP Check-In Receptionist

Ashley Kancler

Chief People Officer

Vice President, Global Talent Management

Vice President, Global Talent Management and Pharmaceutical Development HR

Senior Director, Human Resources

Director, People and Organization Effectiveness

Director, Leadership Development

Chief People Officer at FogPharma

Kristen Stants

Associate Director

Associate Director, Clinical Bioinformatics

Senior Scientist, Computational Biology (Tesaro)

Scientist II

Associate Research Scientist

Postdoctoral Research Scientist

Postdoctoral Associate

Associate Director at FogPharma

Xinwei Han

Senior Director, Biometrics

Biostatisticial Consultant

Senior Director, Head of Biometrics

Lead Biostatistician

Senior Director, Biometrics at Fog Pharma

Lalith Akella

CEO, President and Chairman

Executive Advisor

Board Member

Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Senior Vice President, Cardiovascular diseases, Metabolic diseases, Immunology and Oncology

Senior Vice President, R&D

Chairman and CEO, FogPharma & Former Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Mathai Mammen

Associate Director, Accounting

Manager

Senior Manager, Accounting

Connor Shea

Senior Director

Independent Consultant

Head of Biology

Director/Sr. Director

Principal Scientist - Associate Scientific Fellow

Oncology Drug Discovery Driver

Ben Amidon

Director of Translational Medicine

Director, Clinical Translational Lead - EZH2

Associate Director, Clinical Translational Lead - EZH2

Associate Director, Clinical Biomarker Development/CDx

Director, Oncology Translational Research

Principal Scientist

Research Assistant/Ph.D. Candidate

Public Health Specialist

Ziyang Yu

Senior Director, Discovery Biology

Senior Director, Head of Biology and Pharmacology

Director, Head of Pharmacology

Associate Director, Discovery and Translational Pharmacology

Senior Scientist, Discovery and Translational Pharmacology

Scientist, Discovery and Translational Pharmacology

Instructor in Medicine/Assistant in Genetics

NRSA/NCI Postdoctoral Fellow

NRSA/NIA Predoctoral Fellow

Graduate Student

Brandon Nicolay

Director of Member Services

Task Force Director of Housekeeping at Kimpton Marlowe

Director of Operational Excellence, KAYAK Hotels

General Manager, Kimpton Onyx Hotel

Brand Operations Manager

Hotel Manager, Kimpton Hotel Monaco

I help make experiences better.

Jessica Lavin

Senior Director Medicinal Chemistry

Senior Director, Head of Medicinal Chemistry

Senior Principal Scientist/Medicinal Chemistry Lead

Associate Director of Chemistry

Senior Principal Scientist - Medicinal Chemistry

Jennifer Davoren

EVP & Chief Technical Operations Officer

Member Board of Directors

Biogen

Senior Vice President, Pharmaceutical Development, Engineering and Technology

Vice President, Global Regulatory Affairs

Vice President, Biopharmaceutial Development

Director, Biopharmaceutical Development

Rohin Mhatre

Associate Director Lab Operations

Senior Manager Research Operations

Laboratory Operations Manager

Laboratory Manager

Lab Associate

Lab Manager

Lab specialist

Associate Director Lab Operations at FogPharma

Tucker Lynn

Senior Director Biology

Director

Associate Director, Biology

Associate Director / Principal Scientist

Senior Scientist

Scientist

Core Instrument Manager

Cancer biology and drug discovery

Yaguang Si

Chief Data Officer

Principal Owner

Lecturer (Machine Learning)

Senior Advisor

Advisory Committee Member

Chief Data Officer @ FogPharma | Data Science Leader

Brandon Allgood

Senior Director Clinical Operations

Head of Oncology Delivery, Clinical Delivery & Patient Centricity

Director Clinical Operations

Global Clinical Program Lead

Sr. Clinical Project Manager

Monitoring Manager

Operations and Science Leader

Oncology Lead Clinical Research Associate

Clinical Research Associate

Global Development Operations Leader

Amanda Garofalo

Executive Project Manager

Senior Director of Program Management

Associate Director of Project Management, Chief of Staff

Administrative Business Partner, FogPharma

Heather Grant

news impact assignment basic	general	Mar 1, 2024 10:56 PM	be270ed1
public peers	general
news daily refresh	general	Jul 25, 2024 12:00 PM	69018f7e
news processing daily refresh	general	Jun 3, 2024 7:41 AM	57c9e291
news impact assignment daily	general	Jun 3, 2024 7:44 AM	fe4ec720
news processing basic	general	Mar 1, 2024 10:56 PM	0e13f31f
company summary	general	Jun 3, 2024 7:46 AM	5487e003
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 1, 2024 10:56 PM	157cfce0
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 1, 2024 10:56 PM	82460319
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:FOGPHARMA

FogPharma